Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein-Reference-Cited by-全球学者库

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein

Published:2016-09 Issue:1 Volume:380 Page:163-173
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Wang Yu,Ding Xiwei,Wang Shaoqing,Moser Catherine D.,Shaleh Hassan M.,Mohamed Essa A.,Chaiteerakij Roongruedee,Allotey Loretta K.,Chen Gang,Miyabe Katsuyuki,McNulty Melissa S.,Ndzengue Albert,Barr Fritcher Emily G.,Knudson Ryan A.,Greipp Patricia T.,Clark Karl J.,Torbenson Michael S.,Kipp Benjamin R.,Zhou Jie,Barrett Michael T.,Gustafson Michael P.,Alberts Steven R.,Borad Mitesh J.,Roberts Lewis R.^ORCID

Funder

National Institutes of Health

Mayo Clinic Center for Cell Signaling in Gastroenterology

Mayo Clinic Cancer Center

ARIAD Pharmaceuticals

The Cholangiocarcinoma Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany;von Hahn;Scand. J. Gastroenterol,2011